期刊文献+

阿那曲唑和他莫昔芬对绝经后激素受体阳性转移性乳腺癌患者的疗效及肿瘤相关炎性因子的影响对比 被引量:8

Effects of anadrazole and tamoxifen on efficacy and tumor-associated inflammatory factors in hormone receptor-positive patients with metastatic breast cancer after menopause
下载PDF
导出
摘要 目的比较阿那曲唑和他莫昔芬对绝经后激素受体阳性转移性乳腺癌[HR(+)MBC]患者的疗效及血清肿瘤相关炎性因子表达水平的影响。方法选取50例HR(+)MBC患者,其中使用芳香化酶抑制剂阿那曲唑治疗者26例(阿那曲唑组),使用传统药物他莫昔芬治疗者24例(他莫昔芬组),比较患者的治疗效果以及治疗前后血清白细胞介素(IL)-1、IL-2、IL-6、IL-8、IL-10和肿瘤坏死因子-α(TNF-α)的表达水平。结果阿那曲唑组的临床疗效优于他莫昔芬组(P<0.05)。治疗后,他莫昔芬组IL-1、IL-8、IL-10和TNF-α水平较治疗前下降(均P<0.05),阿那曲唑组IL-1、IL-8、IL-10、TNF-α水平较治疗前降低(均P<0.05),阿那曲唑组IL-1、IL-2、IL-6、IL-8、IL-10、TNF-α水平均低于他莫昔芬组(均P<0.05)。结论阿那曲唑对HR(+)MBC的疗效优于他莫昔芬;两种药物对肿瘤生长相关炎性因子表达水平的影响存在差异,而这种差异可能与疗效密切相关。 Objective To Compare the effects of anadrazole and tamoxifen on the efficacy and expression levels of serum tumor-associated inflammatory factors in patients with hormone receptor-positive metastatic breast cancer[HR( +) MBC]after menopause. Methods Of 50 patients with HR( +) MBC involved,26 patients( anadrazole group) were administered aromatase inhibitor,anadrazole,and 24 patients( tamoxifen group) were administered traditional medicine,tamoxifen. The therapeutic efficacy and the expression levels of serum interleukin( IL)-1,IL-2,IL-6,IL-8,IL-10 and tumor necrosis factor-α( TNF-α) before and after treatment were compared between the two groups.Results The clinical efficacy of the anastrozole group was significantly superior to that of the tamoxifen group( P〈0. 05). After treatment,the levels of IL-1,IL-8,IL-10 and TNF-α decreased in the tamoxifen group compared to the levels before treatment( all P〈0. 05),the levels of IL-1,IL-8,IL-10 and TNF-α decreased in the anadrazole group compared to the levels before treatment( all P〈0. 05),and the levels of IL-1,IL-2,IL-6,IL-8,IL-10 and TNF-α were lower in the anadrazole group than those in the tamoxifen group( all P〈0. 05). Conclusion The efficacy of anastrozole is superior to that of tamoxifen for HR( +) MBC. There is a difference in the effect on the expression levels of tumor-associated inflammatory factors between the two medicines,and that difference might be related to the efficacy closely.
出处 《广西医学》 CAS 2018年第1期4-6,共3页 Guangxi Medical Journal
基金 广东省自然科学基金(2016A030313381) 广东省深圳市战略新兴产业发展专项基金(JCYJ20150529151839281) 广东省深圳市卫生计生系统科研项目(201402025)
关键词 转移性乳腺癌 激素受体阳性 绝经 阿那曲唑 他莫昔芬 炎性因子 Metastatic breast cancer, Positive hormone receptor, Menopause, Anastrozole, Tamoxifen, Inflammatory factor
  • 相关文献

参考文献5

二级参考文献107

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 2Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumours.Nature,2000,406:747-752.
  • 3Maambo EC,Ioffe OB.Molecular classification and prognostication of breast cancer.Pathol Case Rev,2009,14:129-134.
  • 4Carey LA,Perou CM,Livasy CA,et al.Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study.JAMA,2006,295:2492 -2502.
  • 5Ihemelandu CU,Leffall LD Jr,Dewitty RL,et al.Molecular breast cancer subtypes in premenopausaland postmenopausal AfricanAmerican women:age-specific prevalence and survival.J Surg Res,2007,143:109-118.
  • 6Carey LA,Dees EC,Sawyer L,et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res,2007,13:2329-2334.
  • 7von Ahsen N, Binder C, Brockm?ller J, et al. CYP2D6 und tamoxifen: pharmakogenetische neuentdeckung eines etablierten medikaments?/CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug?Lab Med, 2009, 33(5): 293-302.
  • 8Berliere M, Duhoux FP, Dalenc F, et al. Tamoxifen and ovarian function. PLoS One, 2013, 8(6): e66616.
  • 9Harper MJ, Walpole AL. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature, 1966, 212(5057): 87.
  • 10Skidmore J, Walpole AL, Woodburn J. Effect of some triphenylethylenes on oestradiol binding in vitroto macromolecules from uterus and anterior pituitary. J Endocrinol, 1972, 52(2): 289-298.

共引文献1267

同被引文献94

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部